Indication
KRAS p
1 clinical trial
2 products
Clinical trial
A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone MarrowStatus: Recruiting, Estimated PCD: 2025-05-01
Product
AMG 510Product
Docetaxel